29.11.2012 Views

The Ohio Journal of - The Ohio Academy of Science

The Ohio Journal of - The Ohio Academy of Science

The Ohio Journal of - The Ohio Academy of Science

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

A-44 <strong>The</strong> <strong>Ohio</strong> <strong>Journal</strong> <strong>of</strong> <strong>Science</strong><br />

Vol. 112(1)<br />

focal adhesions, is an oncogene. Its activity is regulated<br />

by tyrosine phosphorylation, and data show the tumor<br />

suppressor PTPRT dephosphorylates Paxillin at tyrosine<br />

88 (Y88). Since PTPRT suppresses colorectal cancer<br />

growth, Paxillin Y88 phosphorylation levels are higher in<br />

the tumor than in matched normal control tissue. To study<br />

the implications <strong>of</strong> this phosphorylation event, tyrosine<br />

88 was mutated to phenylalanine (Y88F), which cannot<br />

be phosphorylated. Accordingly, Y88F mutants were less<br />

tumorigenic, growing 20% more slowly than control cells<br />

in cell culture, displaying a 71% reduction <strong>of</strong> anchorage<br />

independent growth, and completely unable to form tumors<br />

in nude mice. However, why Paxillin PY88 is tumorgenic is<br />

still unknown. Since data show that mutants experience<br />

a 10-fold increase in abnormal cytokinetic events and<br />

occurrence <strong>of</strong> multinucleated cells (N = 214 parental cells,<br />

161 Y88F mutant cells), it is hypothesized that Paxillin<br />

PY88 has a role in the cell cycle. To test this hypothesis,<br />

HCT 116 colon cancer cells were arrested at various<br />

stages <strong>of</strong> the cell cycle to determine Paxillin PY88 levels.<br />

Three Western Blot results (n=1) show that Paxillin Y88<br />

phosphorylation occurs preferentially during mitosis.<br />

Western Blot results (n=1) also show that SRC kinase,<br />

an oncogene involved in mitosis, phosphorylates Paxillin<br />

PY88. Ultimately, understanding the role <strong>of</strong> Paxillin PY88<br />

in the cell cycle will better explain how PY88 is tumorigenic.<br />

Poster Board No. 040 SEROTONIN (5 HT) ANTAGONISTS EFFECT<br />

ON MDA - 2B31 BREAST CANCER CELL PROLIFERATION. Aarti<br />

Kumar 1 , kumarhome@yahoo.com, Dr. Laura Hernandez, 2 ,<br />

Ekta Yadav 2 1 William Mason High School, 2 University <strong>of</strong><br />

Cincinnati, 4637 Forest Ridge Drive, Mason, OH 45040<br />

Today, approximately 13.4% <strong>of</strong> women will develop<br />

breast cancer in their lifetime. Breast cancer is the<br />

uncontrolled cell growth <strong>of</strong> regular epithelial cells forming<br />

a malignant tumor through mutations or gene changes.<br />

Serotonin (5-HT) a signaling molecule also known as<br />

5-hydroxytryptophan is significant in the processes <strong>of</strong><br />

the mammary gland. Alteration in 5-HT production and<br />

tryptophan hydroxylase 1 (TPH1) enzyme activity leads<br />

to enhanced proliferation <strong>of</strong> breast cancer cells, which is<br />

opposite to what occurs normally. <strong>The</strong> project hypothesis<br />

was that if the 5HT receptors: 5HTR2B and 5HTR1D are<br />

blocked with receptor antagonist treatments; there will<br />

be less MDA-MB-231 cell proliferation and less Cyclin D1<br />

or mRNA gene expression. <strong>The</strong> methodology included cell<br />

culture <strong>of</strong> MDA-MB231 breast cancer cells, RNA isolation/<br />

cDNA synthesis, reverse transcription, MTT Assay, and<br />

Quantitative PCR (qPCR). Based on the MTT Assay, the<br />

5HTR1D antagonist proved to be more effective, decreasing<br />

proliferation <strong>of</strong> MDA-MB231 cells by more than 37% at<br />

a concentration <strong>of</strong> 100 µm. This analysis is statistically<br />

valid because the T-Test was 0.0007 (< 0.05). <strong>The</strong> 5HTR2B<br />

antagonist decreased Cyclin D1 gene expression from 1.1 to<br />

0.01 relative fold differences at an antagonist concentration<br />

<strong>of</strong> 100 µm. This indicates a 5HTR2B treatment effectively<br />

reduces the amount <strong>of</strong> Cyclin D1 gene expression. <strong>The</strong>se<br />

results support the hypothesis that Cyclin D1 expression<br />

decreases and breast cancer cell proliferation decreases<br />

after antagonist treatment.<br />

Poster Board No. 041 THE REGULATION OF METABOLIC<br />

INFLAMMATION BY MACROPHAGE KLF2. Yasemin Cobanoglu,<br />

ycobanoglu14@gmail.com, Wendy A. Goodman, Yoichi<br />

Takami, Nikunj Sharma, Ganapati H. Mahabaleshwar, G.<br />

Brandon Atkins, Mukesh K. Jain, Case Western Reserve<br />

University, Dept <strong>of</strong> Medicine, Cleveland OH 44106. (Hathaway<br />

Brown)<br />

Metabolic inflammation is associated with obesityinduced<br />

insulin resistance and enhanced susceptibility<br />

to atherosclerosis. Insulin resistance is a chronic<br />

inflammatory condition mediated by activated, tissueresident<br />

macrophages. <strong>The</strong>se macrophages accumulate<br />

in the liver, skeletal muscle, and adipose tissue, and<br />

secrete pro-inflammatory mediators to cause tissue<br />

dysfunction. Current studies explore the role <strong>of</strong> Kruppel-<br />

like Factor 2 (KLF2), a zinc-finger transcription factor, in<br />

modifying metabolic inflammation in vivo. <strong>The</strong> basis <strong>of</strong><br />

the hypothesis states that macrophage KLF2 regulates<br />

metabolic inflammation via repressive effects on NFκB.<br />

Mac-KLF2 ∆/∆ mice develop accelerated obesity when placed<br />

on a high-fat diet, gaining an average <strong>of</strong> 28.7g±0.8g during<br />

20 weeks <strong>of</strong> high-fat feeding, compared to control mice<br />

which gained an average <strong>of</strong> 22.1g±0.6g (p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!